Top

Published in:

01-04-2011 | Colorectal Cancer

Relationship Between Preoperative Comorbidity, Systemic Inflammatory Response, and Survival in Patients Undergoing Curative Resection for Colorectal Cancer

Authors: C. S. D. Roxburgh, MBChB, J. J. Platt, MBChB, E. F. Leitch, MBChB, J. Kinsella, PhD, P. G. Horgan, PhD, D. C. McMillan, PhD

Published in: Annals of Surgical Oncology | Issue 4/2011

Abstract

Background

Besides tumor characteristics, colorectal cancer (CRC) outcomes are also determined by host factors, in particular the systemic inflammatory response. The basis of this relationship with survival is not known; however, systemic inflammation may reflect comorbidity. The present study examines relationships between host factors (including age, comorbidity, deprivation, and systemic inflammation) and survival in CRC.

Methods

A total of 302 patients underwent curative elective CRC resection between 1997 and 2005. Data was collected on patient comorbidity (Charlson Comorbidity Index [CCI], Lee Cardiac Risk Index [LCRI], National Institute on Aging and National Cancer Institute Comorbidity Index [NIA/NCI], and Adult Comorbidity Evaluation-27 [ACE-27]), systemic inflammatory response (Glasgow Prognostic Score [mGPS]), deprivation [Carstairs Deprivation Index], body mass index, and smoking status.

Results

For cancer-specific survival, age (P = 0.047), tumor, node, metastasis system stage (P < 0.001), high-risk Petersen Index (P < 0.001), LCRI (P = 0.021), and mGPS (P < 0.001) were independent factors by multivariate analysis. For overall survival, age (P < 0.001), tumor, node, metastasis system stage (P = 0.001), high-risk Petersen Index (P = 0.002), postoperative infective complications (P = 0.002), ACE-27 (P = 0.008), and mGPS (P < 0.001) were independent factors. Older age related to increasing comorbidity (ACE-27, CCI, LCRI [P < 0.005]) and increased mGPS (P < 0.005). Smoking and deprivation related to increasing comorbidity (P < 0.05). The mGPS was associated with high comorbidity burden assessed with ACE-27 (P = 0.065), CCI (P = 0.016), LCRI (P = 0.095), and NIA/NCI (P = 0.084).

Conclusions

Comorbidity does not fully explain the relationship between the mGPS and cancer-specific survival in CRC patients. Furthermore, comorbidity, in particular that measured by the LCRI, is an important independent indicator of cancer survival.

Cancerstats 2004. Available at: http://info.cancerresearchuk.org/cancerstats/types/bowel/. Accessed 30 Oct 2010.

McArdle CS, Hole DJ. Outcome following surgery for colorectal cancer: analysis by hospital after adjustment for case-mix and deprivation. Br J Cancer. 2002;86:331–5.PubMedCrossRef

Verdecchia A, Francisci S, Brenner H, et al. EUROCARE-4 Working Group. Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007;8:784–96.PubMedCrossRef

McMillan DC, Wotherspoon HA, Fearon KC, et al. A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. Am J Surg. 1995;170:319–22.PubMedCrossRef

Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6:149–63.PubMedCrossRef

Ishizuka M, Nagata H, Takagi K, Horie T, Kubota K. Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg. 2007;246:1047–51.PubMedCrossRef

Koike Y, Miki C, Okugawa Y, et al. Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. J Surg Oncol. 2008;98:540–4.PubMedCrossRef

Roxburgh CSD, Crozier JE, Maxwell F, et al. Comparison of tumour-based (Petersen Index) and inflammation-based (Glasgow Prognostic Score) scoring systems in patients undergoing curative resection for colon cancer. Br J Cancer. 2009;100:701–6.PubMedCrossRef

Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349:462–6.PubMedCrossRef

10.

Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–26.PubMedCrossRef

11.

Lloyd-Jones DM, Levy D. C-reactive protein in the prediction of cardiovascular events. N Engl J Med. 2003;348:1059–61.PubMedCrossRef

12.

Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131–5.PubMedCrossRef

13.

Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation. 2003;107:391–7.PubMedCrossRef

14.

Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly. Diabetes. 2001;50:2384–9.PubMedCrossRef

15.

Freeman DJ, Norrie J, Caslake MJ, et al. West of Scotland Coronary Prevention Study. Diabetes. 2002;61:1596–600.CrossRef

16.

Festa A, D’Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute phase proteins and plasminogen activator inhibitor-1 predict the development of type two diabetes. Diabetes. 2002;51:1131–7.CrossRef

17.

Dehghan A, Kardys I, de Maat MPM, et al. Genetic variation, C-reactive protein levels and incidence of diabetes. Diabetes. 2007;56:872–9.PubMedCrossRef

18.

Fröhlich M, Sund M, Löwel H, et al. Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J. 2003;24:1365–72.PubMedCrossRef

19.

Roxburgh CSD, McMillan DC. Re: Comparison of the prognostic value of inflammation based pathological and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer (letter). Ann Surg. 2010;251(2):390–1.CrossRef

20.

Yancik R, Wesley MN, Ries LA, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer. 1998;82:2123–34.PubMedCrossRef

21.

Janssen-Heijnen ML, Houterman S, Lemmens VE, et al. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol. 2005;55:231–40.PubMedCrossRef

22.

Iversen LH, Nørgaard M, Jacobsen J, Laurberg S, Sørensen HT. The impact of comorbidity on survival of Danish colorectal cancer patients from 1995 to 2006—a population-based cohort study. Dis Colon Rectum. 2009;52:71–8.PubMed

23.

Hines RB, Chatla C, Bumpers HL, et al. Predictive capacity of three comorbidity indices in estimating mortality after surgery for colon cancer. J Clin Oncol. 2009;27:4339–45.PubMedCrossRef

24.

Williams TJ, Quirke P, Shepherd NA. RCPath Cancer Services Working Group. Dataset for colorectal cancer. 2nd ed, September 2007. Available at: http://www.rcpath.org.uk. Accessed 30 Oct 2010.

25.

Petersen VC, Baxter KJ, Love SB, Shepherd NA. Identification of objective pathological prognostic determinants and models of prognosis in Dukes’ B colon cancer. Gut. 2002;51:65–9.PubMedCrossRef

26.

Morris EJ, Maughan NJ, Forman D, Quirke P. Who to treat with adjuvant therapy in Dukes’ B/stage II colorectal cancer? The need for high quality pathology. Gut. 2007;56:1419–25.PubMedCrossRef

27.

Moyes LH, Leitch EF, McKee RF, et al. Pre-operative systemic inflammation predicts postoperative infectious complications in patients undergoing curative resection for colorectal cancer. Br J Cancer. 2009;100:1236–9.PubMedCrossRef

28.

Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRef

29.

Havlik RJ, Yancik R, Long S, Ries L, Edwards B. The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer. 1994;74(7 Suppl):2101–6.PubMedCrossRef

30.

Janssen-Heijnen ML, Maas HA, Houterman S, et al. Comorbidity in older surgical cancer patients: influence on patient care and outcome. Eur J Cancer. 2007;43:2179–93.PubMedCrossRef

31.

Piccirillo JF, Creech CM, Zequeira R, Anderson S, Johnston AS. Inclusion of comorbidity into oncology data registries. J Registry Manage. 1999;26:66–70.

32.

Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291:2441–7.PubMedCrossRef

33.

Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999;100:1043–9.PubMed

34.

Hoeks SE, op Reimer WJ, van Gestel YR, et al. Preoperative cardiac risk index predicts long-term mortality and health status. Am J Med. 2009;122:559–65.PubMedCrossRef

35.

Carstairs V, Morris R. Deprivation and Health in Scotland. Aberdeen: Aberdeen University Press, 1991.

36.

Information Services Division Scotland. Available at: http://www.isdscotland.org. Accessed 30 Oct 2010.

37.

Hole DJ, McArdle CS. Impact of socioeconomic deprivation on outcome after surgery for colorectal cancer. Br J Surg. 2002;89:586–90.PubMedCrossRef

38.

Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89:1028–30.PubMedCrossRef

39.

McMillan DC. An inflammation-based prognostic score and its role in the nutrition based management of patients with cancer. Proc Nutr Soc. 2008;67:257–62.PubMedCrossRef

40.

McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 2007;22:81–6.CrossRef

41.

Chan AO, Jim MH, Lam KF, et al. Prevalence of colorectal neoplasm among patients with newly diagnosed coronary artery disease. JAMA. 2007;298:1412–9.PubMedCrossRef

42.

McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12:223–6.PubMedCrossRef

43.

Siddiqui AA, Nazario H, Mahgoub A, et al. For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes. Dig Dis Sci. 2009;54:1307–11.PubMedCrossRef

Title: Relationship Between Preoperative Comorbidity, Systemic Inflammatory Response, and Survival in Patients Undergoing Curative Resection for Colorectal Cancer
Authors: C. S. D. Roxburgh, MBChB
J. J. Platt, MBChB
E. F. Leitch, MBChB
J. Kinsella, PhD
P. G. Horgan, PhD
D. C. McMillan, PhD
Publication date: 01-04-2011
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 4/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-010-1410-8

2024 ASCO Annual Meeting

Springer Medicine

Relationship Between Preoperative Comorbidity, Systemic Inflammatory Response, and Survival in Patients Undergoing Curative Resection for Colorectal Cancer

Abstract

Background

Methods

Results

Conclusions

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2011

Hepatic Stellate Cells Accelerate the Malignant Behavior of Cholangiocarcinoma Cells

The “Tipping Point” for Breast Cancer Mortality Decline Has Resulted from Size Reductions Due to Mammographic Screening

Clinicopathological Assessment of Locally Recurrent Rectal Cancer and Relation to Local Re-Recurrence

Is Delayed Liver Resection Appropriate for Patients with Metachronous Colorectal Metastases?

Disease-Related Mortality within the First Year after Subtotal Esophagectomy for Cancer

Perioperative Complications of Breast Cancer Surgery in Elderly Women (≥80 Years)